Stay updated on Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Clinical Trial page.

Latest updates to the Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Clinical Trial page
- Check7 days agoChange DetectedThe page has removed extensive details about a randomized phase II study of pembrolizumab in esophageal adenocarcinoma, including the study's aims, inclusion and exclusion criteria, and the principal investigator's name. It has added a new version number and the name of a collaborator.SummaryDifference37%
- Check14 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 19, 2025.SummaryDifference0.2%
- Check22 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check29 days agoChange DetectedThe page has updated its date references, removing older dates from 2024 and adding new dates in March 2025. This indicates a shift in the timeline of the content presented.SummaryDifference0.8%
- Check58 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check72 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Clinical Trial page.